Obviously, SMOC1 expression was significantly downregulated in bladder urothelial carcinoma, breast invasive carcinoma (BRCA), cholangiocarcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, prostate adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma, whereas the expression of SMOC1 was increased in kidney chromophobe and LUAD. This evidence concerns the gene SMOC1 and prostate adenocarcinoma.